116 related articles for article (PubMed ID: 37020390)
21. Expression and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in tamoxifen-treated breast cancer patients.
Jahangiri R; Jamialahmadi K; Gharib M; Emami Razavi A; Mosaffa F
Gene; 2019 Feb; 685():24-31. PubMed ID: 30359738
[TBL] [Abstract][Full Text] [Related]
22. The effect of 14-3-3ζ expression on tamoxifen resistance and breast cancer recurrence: a Danish population-based study.
Thistle JE; Hellberg Y; Mortensen K; Hamilton-Dutoit S; Kjærsgaard A; Cronin-Fenton D; Sørensen HT; Lash TL
Breast Cancer Res Treat; 2017 Oct; 165(3):633-643. PubMed ID: 28643021
[TBL] [Abstract][Full Text] [Related]
23. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
24. Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
Zeng Q; Lin X; Chen H; Yan Y; Wang X
Breast Cancer; 2022 May; 29(3):458-467. PubMed ID: 35041152
[TBL] [Abstract][Full Text] [Related]
25. POR overexpression induces tamoxifen-resistance in breast cancer through the STAT1/c-Myc pathway.
Chen S; Wu D; Liu Q; Jin F; Yao F; Fang Y
Mol Carcinog; 2023 Feb; 62(2):249-260. PubMed ID: 36321415
[TBL] [Abstract][Full Text] [Related]
26. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
[TBL] [Abstract][Full Text] [Related]
27. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
28. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
29. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women.
Wege AK; Chittka D; Buchholz S; Klinkhammer-Schalke M; Diermeier-Daucher S; Zeman F; Ortmann O; Brockhoff G
Breast Cancer Res; 2018 Nov; 20(1):139. PubMed ID: 30458882
[TBL] [Abstract][Full Text] [Related]
30. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
[TBL] [Abstract][Full Text] [Related]
31. Estrogen-regulated AGR3 activates the estrogen receptor signaling pathway to promote tamoxifen resistance in breast cancer.
Jiang R; Sun Y; Chen X; Shi P
Breast Cancer Res Treat; 2021 Nov; 190(2):203-211. PubMed ID: 34519905
[TBL] [Abstract][Full Text] [Related]
32. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
[TBL] [Abstract][Full Text] [Related]
33. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
34. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
35. Ceramide kinase confers tamoxifen resistance in estrogen receptor-positive breast cancer by altering sphingolipid metabolism.
Huang C; Su L; Chen Y; Wu S; Sun R; Xu Q; Qiu X; Yang C; Kong X; Qin H; Zhao X; Jiang X; Wang K; Zhu Y; Wong PP
Pharmacol Res; 2023 Jan; 187():106558. PubMed ID: 36410675
[TBL] [Abstract][Full Text] [Related]
36. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
37. LncRNA DILA1 inhibits Cyclin D1 degradation and contributes to tamoxifen resistance in breast cancer.
Shi Q; Li Y; Li S; Jin L; Lai H; Wu Y; Cai Z; Zhu M; Li Q; Li Y; Wang J; Liu Y; Wu Z; Song E; Liu Q
Nat Commun; 2020 Nov; 11(1):5513. PubMed ID: 33139730
[TBL] [Abstract][Full Text] [Related]
38. Tamoxifen resistance: from cell culture experiments towards novel biomarkers.
Nass N; Kalinski T
Pathol Res Pract; 2015 Mar; 211(3):189-97. PubMed ID: 25666016
[TBL] [Abstract][Full Text] [Related]
39. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.
Karlsson E; Veenstra C; Emin S; Dutta C; Pérez-Tenorio G; Nordenskjöld B; Fornander T; Stål O
Breast Cancer Res Treat; 2015 Aug; 153(1):31-40. PubMed ID: 26208487
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
